New lab-made drug pair tested on glioblastoma cells
Original title: Design, synthesis, and in vitro antiproliferative evaluation of dasatinib/HO-1 inhibitor codrugs towards glioblastoma therapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on cells in a lab dish.
The short version
Scientists built new drug combinations and tested them on brain tumor cells in a lab dish.
What was studied. Researchers made three new compounds. Each one joined a cancer drug called dasatinib with a blocker of a protein called HO-1. They tested the compounds on lab-grown glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary cells.
What they found. Two out of three new compounds blocked the HO-1 protein. All three still blocked a second target, a protein called cSRC. One compound, called TC7, slowed the growth of glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary cells in the dish and stayed stable for more than 24 hours.
What this means, and what it doesn't
What it could mean: Nothing changes for patients today. This early work hints at a new way to attack glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary cells. The authors say the compound still needs more work before it can move ahead.
What it doesn't mean: This is not a treatment. The tests were done on cells in a dish, not in animals or people. No one knows yet if it is safe or if it helps in the body. It is not a cure, and it is far from everyday care.
Source: PubMed, October 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.